image
Healthcare - Biotechnology - NASDAQ - US
$ 4.765
-9.42 %
$ 8.28 M
Market Cap
-1.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CDIO stock under the worst case scenario is HIDDEN Compared to the current market price of 4.76 USD, Cardio Diagnostics Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CDIO stock under the base case scenario is HIDDEN Compared to the current market price of 4.76 USD, Cardio Diagnostics Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CDIO stock under the best case scenario is HIDDEN Compared to the current market price of 4.76 USD, Cardio Diagnostics Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CDIO

image
$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.0$5.0$5.0$0.0$0.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
34.9 K REVENUE
104.45%
-8.37 M OPERATING INCOME
-15.51%
-8.38 M NET INCOME
-0.08%
-4.99 M OPERATING CASH FLOW
11.97%
-404 K INVESTING CASH FLOW
49.11%
11.9 M FINANCING CASH FLOW
228.74%
940 REVENUE
-79.17%
-1.63 M OPERATING INCOME
-7.53%
-1.64 M NET INCOME
-7.62%
-1.4 M OPERATING CASH FLOW
-0.56%
-47.4 K INVESTING CASH FLOW
13.18%
3.31 M FINANCING CASH FLOW
-54.62%
Balance Sheet Cardio Diagnostics Holdings, Inc.
image
Current Assets 8.79 M
Cash & Short-Term Investments 7.83 M
Receivables 18.6 K
Other Current Assets 945 K
Non-Current Assets 1.82 M
Long-Term Investments 0
PP&E 1.11 M
Other Non-Current Assets 719 K
73.74 %8.90 %10.41 %6.78 %Total Assets$10.6m
Current Liabilities 632 K
Accounts Payable 87.7 K
Short-Term Debt 0
Other Current Liabilities 544 K
Non-Current Liabilities 426 K
Long-Term Debt 0
Other Non-Current Liabilities 426 K
8.29 %51.44 %40.27 %Total Liabilities$1.1m
EFFICIENCY
Earnings Waterfall Cardio Diagnostics Holdings, Inc.
image
Revenue 34.9 K
Cost Of Revenue 0
Gross Profit 34.9 K
Operating Expenses 8.4 M
Operating Income -8.37 M
Other Expenses 17.6 K
Net Income -8.38 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)35k035k(8m)(8m)(18k)(8m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-23977.86% OPERATING MARGIN
-23977.86%
-24028.24% NET MARGIN
-24028.24%
-87.71% ROE
-87.71%
-78.98% ROA
-78.98%
-83.80% ROIC
-83.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cardio Diagnostics Holdings, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)20212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -8.38 M
Depreciation & Amortization 276 K
Capital Expenditures -215 K
Stock-Based Compensation 2.59 M
Change in Working Capital 523 K
Others 692 K
Free Cash Flow -5.21 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cardio Diagnostics Holdings, Inc.
image
CDIO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Cardio Diagnostics Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
89.8 K USD 3
9-12 MONTHS
7. News
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has regained compliance with Nasdaq minimum bid price. businesswire.com - 2 weeks ago
Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has the continued expansion of its reach with a new cohort of healthcare practices across the United States. businesswire.com - 4 weeks ago
Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025. businesswire.com - 1 month ago
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo. businesswire.com - 2 months ago
Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced that the Company has partnered with seven new provider organizations. businesswire.com - 4 months ago
Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced their PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from CMS. businesswire.com - 6 months ago
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS. businesswire.com - 8 months ago
Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum. businesswire.com - 11 months ago
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit. businesswire.com - 1 year ago
Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the MolDx program. businesswire.com - 1 year ago
Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO) Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and ARCA biopharma (NASDAQ:ABIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Profitability This table compares Cardio Diagnostics and ARCA biopharma’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Cardio Diagnostics -34,911.87% -415.33% -216.10% ARCA biopharma N/A -16.08% -15.51% Analyst Ratings This is a summary of current ratings and target prices for Cardio Diagnostics and ARCA biopharma, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 0 2 0 3.00 ARCA biopharma 0 0 0 0 N/A Cardio Diagnostics presently has a consensus price target of $1.35, indicating a potential upside of 84.93%. Given Cardio Diagnostics’ higher probable upside, equities analysts clearly believe Cardio Diagnostics is more favorable than ARCA biopharma. Volatility & Risk Cardio Diagnostics has a beta of 5.3, meaning that its share price is 430% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Earnings & Valuation This table compares Cardio Diagnostics and ARCA biopharma’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardio Diagnostics $20,000.00 828.19 -$8.38 million N/A N/A ARCA biopharma N/A N/A -$5.34 million ($0.42) -7.93 ARCA biopharma has lower revenue, but higher earnings than Cardio Diagnostics. Institutional and Insider Ownership 8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 30.9% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Summary ARCA biopharma beats Cardio Diagnostics on 6 of the 10 factors compared between the two stocks. About Cardio Diagnostics (Get Free Report) Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois. About ARCA biopharma (Get Free Report) ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. https://www.defenseworld.net - 1 year ago
Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood tests are now available at FMS' newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. businesswire.com - 1 year ago
8. Profile Summary

Cardio Diagnostics Holdings, Inc. CDIO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 8.28 M
Dividend Yield 0.00%
Description Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Contact 400 N Aberdeen St, Chicago, IL, 60642 https://cardiodiagnosticsinc.com
IPO Date Jan. 14, 2022
Employees 13
Officers Ms. Elisa Michael Luqman Esq., J.D., M.B.A. Chief Financial Officer & Principal Accounting Officer Ms. Khullani Abdullahi J.D. Vice President of Revenue & Strategy Mr. Timur Dogan Ph.D. Chief Technology Officer Dr. Meeshanthini V. Dogan Ph.D. Co-Founder, Chief Executive Officer & Director Dr. Robert A. Philibert M.D., Ph.D. Co-Founder, Chief Medical Officer & Director